HIG1 hypoxia inducible domain family member 1A pseudogene 10Genealiases: []
Q-omics provides the consensus-scored HIGD1AP10 profile across patient tissues and cancer cell-line models. HIGD1AP10 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, HIGD1AP10 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, HIGD1AP10 RNA expression shows 5,669 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, THCA, and STAD as cancer lineages where HIGD1AP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD1AP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD1AP10 survival associations across molecular data types. HIGD1AP10 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD1AP10 RNA expression–survival associations across cancer types. High HIGD1AP10 expression shows unfavorable associations in LUSC, MESO, UCEC, PAAD, LUAD and CHOL. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify LUSC as the clearest survival context for HIGD1AP10 RNA expression.
This table summarizes HIGD1AP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HIGD1AP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD1AP10 shows lower tumor expression in THCA, READ and KIRC. The THCA box plot shows higher HIGD1AP10 RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p = .003).
This table shows molecular features associated with HIGD1AP10 in patient tissues and cancer cell lines. In patient samples, HIGD1AP10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
